William Blair analyst Matt Phipps has maintained their bullish stance on JBIO stock, giving a Buy rating today.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Matt Phipps has given his Buy rating due to a combination of factors tied to Jade Biosciences’s advancing pipeline and upcoming clinical catalysts. He highlights that the forthcoming JADE101 data at the European Renal Association meeting will offer an initial view of pharmacokinetics, pharmacodynamics, and the Phase II design in IgA nephropathy, which should clarify dosing strategies and support the company’s development trajectory.
He notes that investor attention is centered on the extent of IgA reduction and feasible dosing intervals, with a 55% decline and every-eight-week dosing viewed as the current base expectation embedded in the stock. Phipps also points to the broader platform value, citing the planned Phase I start for JADE201 in 2026 and JADE301 in 2027, which together provide a visible multi-asset pipeline and justify a positive stance despite the stock’s strong year-to-date performance.
According to TipRanks, Phipps is a 4-star analyst with an average return of 5.3% and a 44.72% success rate. Phipps covers the Healthcare sector, focusing on stocks such as Tenax Therapeutics, Compass Therapeutics, and Evommune, Inc..